Small cell lung cancer (SCLC) is a highly malignant, rapidly progressing, poorly prognostic, and highly recurrent difficult-to-treat tumor. For more than 30 years, patients with limited-stage SCLC have been treated with a combination of thoracic radiotherapy and chemotherapy. For those who achieve good response, prophylactic cranial irradiation is recommended. But there is no consensus on the optimal dosage-fractionation for thoracic radiotherapy in limited-stage SCLC. In this article, a series of related studies conducted in recent years were reviewed.

Small cell lung cancer (SCLC) is a highly malignant, rapidly progressing, poorly prognostic, and highly recurrent difficult-to-treat tumor. For more than 30 years, patients with limited-stage SCLC have been treated with a combination of thoracic radiotherapy and chemotherapy. For those who achieve good response, prophylactic cranial irradiation is recommended. But there is no consensus on the optimal dosage-fractionation for thoracic radiotherapy in limited-stage SCLC. In this article, a series of related studies conducted in recent years were reviewed.